Health Condition 1: T31- Burns classified according to extent of body surface involved
Conditions
Interventions
Intervention1: Metformin group: 500 mg of metformin administered orally or via nasogastric tube twice daily (total daily dose of 1 g) for 7 days or until ICU discharge, whichever occurs first.
Control
Sponsors
All India Institute of Medical Sciences (AIIMS) New Delhi.
Eligibility
Inclusion criteria
Inclusion criteria: 1. Adults aged 18–60 years. 2. Burns covering 20–60 percentage of TBSA. 3.Provision of informed consent by the patient or legal representative. 4. Hemodynamically stable.
Exclusion criteria
Exclusion criteria: 1. Known history of diabetes mellitus. 2. Serum creatinine greater than 1.5 mg/dL 3. Hepatic dysfunction (AST or ALT greater than 3 times the upper limit of normal). 4. Presence of lactic acidosis or metabolic acidosis. 5. Pregnancy or lactation. 6. Participation in another interventional clinical trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To evaluate the effects of Metformin on Serum levels of CRP, IL-6, Serum Ferritin, and PCT in adult burn patients with. 20-60 percentage of TBSA injuries.Timepoint: Till 7 days of ICU admission or till discharge whichever is earlier | — |
Secondary
| Measure | Time frame |
|---|---|
| To assess the impact of metformin on clinical outcomes, including: a. Sequential Organ Failure Assessment (SOFA) score b. Length of ICU stay c. Incidence of sepsis (as per CDC criteria) To monitor the safety and tolerability of metformin in the study populationTimepoint: Till 7 days of icu admission | — |
Countries
India
Contacts
Public ContactRupavath Ramkumar
All India Institute of Medical Sciences (AIIMS), New Delhi.
Outcome results
None listed